Thank you, Mr. Webber.
I'm told I have one minute.
Pardon me if you've covered this point already, but I want to be clear I understand this. Pharmac recently commissioned the “mind the gap” research study in response to commentary that suggested that access to cancer medicine in New Zealand results in poorer health outcomes compared to Australia. I'm told the study showed that more medicines didn't mean better health outcomes. Out of the 35 cancer medicines not funded in New Zealand, only three offered clinically meaningful benefits, with Pharmac already funding one of them, pertuzumab for breast cancer, and considering funding for the other two.
The study concluded that:
A policy of funding more new cancer medicines in order to achieve numerical parity with Australia or other countries would not result in substantive health improvement and would cost significantly more....
Do you have any comment on that conclusion by Pharmac?